Vivus/KV EvaMist approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approves Vivus' metered-dose topical estradiol spray EvaMist to treat moderate to severe vasomotor symptoms due to menopause. The July 27 approval triggers a $140 million payment to Vivus from KV Pharmaceutical, which will market the drug with its more than 280-strong sales force. Vivus received a $10 million up-front payment and is eligible to get more money based on sales milestones. The firm is touting EvaMist's safety profile, but will be competing in a crowded transdermal estradiol market with close competitors Esprit Pharma's Estrasorb, Ascend's EstroGel and BioSante's Elestrin. Vivus is also developing an obesity combo agent, Qnexa (1Pharmaceutical Approvals Monthly September 2006, p. 11)...
You may also be interested in...
Vivus Plans Evamist NDA In Q4 2006, But Obesity Combo Qnexa Is Top Priority
While Vivus is getting ready to submit its NDA for Evamist early in the fourth quarter of 2006, the company is calling its obesity drug Qnexa a potential blockbuster and earmarking it as its top priority.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.